About Us


BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.


Found 31 results
Filters: Author is Wu, Juan  [Clear All Filters]
A. E. DeZern, Eapen, M., Wu, J., Talano, J. - A., Solh, M., Saldaña, B. J. Dávila, Karanes, C., Horwitz, M. E., Mallhi, K., Arai, S., Farhadfar, N., Hexner, E., Westervelt, P., Antin, J. H., H Deeg, J., Leifer, E., Brodsky, R. A., Logan, B. R., Horowitz, M. M., Jones, R. J., and Pulsipher, M. A., Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial., Lancet Haematol, 2022.
Q. Bashir, Nishihori, T., Pasquini, M. C., Martens, M. J., Wu, J., Alsina, M., Anasetti, C., Brunstein, C., Dawson, P., Efebera, Y., Gasparetto, C., Geller, N., Giralt, S., Hall, A. C., Koreth, J., McCarthy, P., Scott, E., Stadtmauer, E. A., Vesole, D. H., and Hari, P., A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial., Transplant Cell Ther, 2022.
L. Luznik, Pasquini, M. C., Logan, B., Soiffer, R. J., Wu, J., Devine, S. M., Geller, N., Giralt, S., Heslop, H. E., Horowitz, M. M., Jones, R. J., Litzow, M. R., Mendizabal, A., Muffly, L., Nemecek, E. R., O'Donnell, L., O'Reilly, R. J., Palencia, R., Schetelig, J., Shune, L., Solomon, S. R., Vasu, S., Ho, V. T., and Perales, M. - A., Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies., J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.
R. F. Ambinder, Wu, J., Logan, B., Durand, C. M., Shields, R., Popat, U. R., Little, R. F., McMahon, D. K., Cyktor, J., Mellors, J. W., Ayala, E., Kaplan, L. D., Noy, A., Jones, R. J., Howard, A., Forman, S. J., Porter, D., Arce-Lara, C., Shaughnessy, P., Sproat, L., Hashmi, S. K., Mendizabal, A. M., Horowitz, M. M., Navarro, W. H., and Alvarnas, J. C., Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial., Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2160-2166, 2019.
J. Paul, Nakasone, H., Sahaf, B., Wu, F., Wang, K., Ho, V., Wu, J., Kim, H., Blazar, B., Ritz, J., Howard, A., Cutler, C., and Miklos, D., A confirmation of chronic graft--host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation., Haematologica, vol. 104, no. 7, pp. e314-e317, 2019.
A. A. King, McKinstry, R. C., Wu, J., Eapen, M., Abel, R., Varughese, T., Kamani, N., and Shenoy, S., Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601., Biol Blood Marrow Transplant, vol. 25, no. 5, pp. e174-e178, 2019.
J. Bolaños-Meade, Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Bin Chen, Y. -, Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J., Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C., and Koreth, J., Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with , Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.
S. G. Holtan, DeFor, T. E., Panoskaltsis-Mortari, A., Khera, N., Levine, J. E., Flowers, M. E. D., Lee, S. J., Inamoto, Y., Chen, G. L., Mayer, S., Arora, M., Palmer, J., Cutler, C. S., Arai, S., Lazaryan, A., Newell, L. F., Jagasia, M. H., Pusic, I., Wood, W. A., Renteria, A. S., Yanik, G., Hogan, W. J., Hexner, E., Ayuk, F., Holler, E., Bunworasate, U., Efebera, Y. A., Ferrara, J. L. M., Pidala, J., Howard, A., Wu, J., Bolaños-Meade, J., Ho, V., Alousi, A., Blazar, B. R., Weisdorf, D. J., and MacMillan, M. L., Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802., Blood Adv, vol. 2, no. 15, pp. 1882-1888, 2018.
P. A. Carpenter, Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., Kitko, C. L., Bolaños-Meade, J., Sarantopoulos, S., Alousi, A. M., Abhyankar, S., Waller, E. K., Mendizabal, A., Zhu, J., O'Brien, K. A., Lazaryan, A., Wu, J., Nemecek, E. R., Pavletic, S. Z., Cutler, C. S., Horowitz, M. M., and Arora, M., A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801., Haematologica, vol. 103, no. 11, pp. 1915-1924, 2018.
H. S. L. Jim, Sutton, S., Majhail, N. S., Wood, W. A., Jacobsen, P. B., Wingard, J. R., Wu, J., Knight, J. M., Syrjala, K. L., and Lee, S. J., Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial., Bone Marrow Transplant, vol. 53, no. 8, pp. 1038-1043, 2018.
S. J. Lee, Logan, B., Westervelt, P., Cutler, C., Woolfrey, A., Khan, S. P., Waller, E. K., Maziarz, R. T., Wu, J., Shaw, B. E., Confer, D., Horowitz, M. M., and Anasetti, C., Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial., JAMA Oncol, vol. 2, no. 12, pp. 1583-1589, 2016.
J. - A. H. Young, Logan, B. R., Wu, J., Wingard, J. R., Weisdorf, D. J., Mudrick, C., Knust, K., Horowitz, M. M., Confer, D. L., Dubberke, E. R., Pergam, S. A., Marty, F. M., Strasfeld, L. M., Brown, J. Wes M., Langston, A. A., Schuster, M. G., Kaul, D. R., Martin, S. I., and Anasetti, C., Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors., Biol Blood Marrow Transplant, vol. 22, no. 2, pp. 359-370, 2016.
W. A. Wood, Le-Rademacher, J., Syrjala, K. L., Jim, H., Jacobsen, P. B., Knight, J. M., Abidi, M. H., Wingard, J. R., Majhail, N. S., Geller, N. L., J Rizzo, D., Fei, M., Wu, J., Horowitz, M. M., and Lee, S. J., Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902)., Cancer, vol. 122, no. 1, pp. 91-8, 2016.
G. G. Laport, Wu, J., Logan, B., Bachanova, V., Hosing, C., Fenske, T., Longo, W., Devine, S. M., Nademanee, A., Gersten, I., Horowitz, M., Lazarus, H. M., and Riches, M. L., Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ, Biol Blood Marrow Transplant, vol. 22, no. 8, pp. 1440-1448, 2016.
S. Shenoy, Eapen, M., Panepinto, J. A., Logan, B. R., Wu, J., Abraham, A., Brochstein, J., Chaudhury, S., Godder, K., Haight, A. E., Kasow, K. A., Leung, K., Andreansky, M., Bhatia, M., Dalal, J., Haines, H., Jaroscak, J., Lazarus, H. M., Levine, J. E., Krishnamurti, L., Margolis, D., Megason, G. C., Yu, L. C., Pulsipher, M. A., Gersten, I., DiFronzo, N., Horowitz, M. M., Walters, M. C., and Kamani, N., A trial of unrelated donor marrow transplantation for children with severe sickle cell disease., Blood, vol. 128, no. 21, pp. 2561-2567, 2016.
P. B. Jacobsen, Le-Rademacher, J., Jim, H., Syrjala, K., Wingard, J. R., Logan, B., Wu, J., Majhail, N. S., Wood, W., J Rizzo, D., Geller, N. L., Kitko, C., Faber, E., Abidi, M. H., Slater, S., Horowitz, M. M., and Lee, S. J., Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902., Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1530-6, 2014.
E. K. Waller, Logan, B. R., Harris, W. A. C., Devine, S. M., Porter, D. L., Mineishi, S., McCarty, J. M., Gonzalez, C. E., Spitzer, T. R., Krijanovski, O. I., Linenberger, M. L., Woolfrey, A., Howard, A., Wu, J., Confer, D. L., and Anasetti, C., Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201., J Clin Oncol, vol. 32, no. 22, pp. 2365-72, 2014.
M. Eapen, O'Donnell, P., Brunstein, C. G., Wu, J., Barowski, K., Mendizabal, A., and Fuchs, E. J., Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies., Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1485-92, 2014.
G. A. Yanik, Horowitz, M. M., Weisdorf, D. J., Logan, B. R., Ho, V. T., Soiffer, R. J., Carter, S. L., Wu, J., Wingard, J. R., DiFronzo, N. L., Ferrara, J. L., Giralt, S., Madtes, D. K., Drexler, R., White, E. S., and Cooke, K. R., Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-64, 2014.
C. Cutler, Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W. J., Pasquini, M., MacMillan, M. L., Hsu, J. W., Waller, E. K., Grupp, S., McCarthy, P., Wu, J., Hu, Z. - H., Carter, S. L., Horowitz, M. M., and Antin, J. H., Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT., Blood, vol. 124, no. 8, pp. 1372-7, 2014.